ReviewKidney international reports2023
Targeting the Endothelin A Receptor in IgA Nephropathy.
Review in Kidney international reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- IgA nephropathy: an overview of the disease, its pathophysiology, and involvement of the gut-kidney axis.Kidney international supplements · 2026Review
- Approved therapies in the IgA nephropathy armamentarium: a summary of the evidence.Kidney international supplements · 2026Review
- Management of IgA nephropathy and the expanding role of immunomodulation.Kidney international supplements · 2026Review
- The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers.Advances in therapy · 2026Article
- Activation of the Endothelin System in Chronic Kidney Disease and Kidney Transplant Recipients-Implications for Disease Progression.International journal of molecular sciences · 2026Article
- Characterization of Atrasentan Metabolic Pathway in Human Liver Microsomes Using Feature-Based Molecular Networking.Pharmaceutics · 2026Article
- The role of endothelin receptor antagonists in kidney disease.Renal failure · 2025Review
- IgA Nephropathy: An Overview of the Clinical Trials.Kidney medicine · 2025Review
- Review
- G-Protein-Coupled Receptors in Chronic Kidney Disease Induced by Hypertension and Diabetes.Cells · 2025Review
- From Despair to Promise: The Dawn of Novel Treatment in IgA Nephropathy.Journal of the American Society of Nephrology : JASN · 2025Article
- G protein-coupled receptor-mediated renal fibrosis: a key focus on kidney disease drug development.Frontiers in pharmacology · 2025Review
- The pathogenesis of IgA nephropathy and implications for treatment.Nature reviews. Nephrology · 2025Review
- Case Report: Bevacizumab-induced renal-limited TMA and FSGS-like lesions in a kidney transplant recipient.Frontiers in oncology · 2025Article
- Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy.Kidney international reports · 2025Article
- The road ahead: emerging therapies for primary IgA nephropathy.Frontiers in nephrology · 2025Review
- Exploring the Relationship Between 91 Inflammatory Cytokines and IgA Nephropathy Using a Two-Sample Mendelian Randomization Study and the Gene Expression Omnibus Database.Mediators of inflammation · 2025Article
- The Influence of Anti-ETAR and Anti-CXCR3 Antibody Levels on the Course of Specific Glomerulonephritis Types.Journal of clinical medicine · 2024Article
- Endothelin Inhibitors in Chronic Kidney Disease: New Treatment Prospects.Journal of clinical medicine · 2024Review
- Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease.Clinical science (London, England : 1979) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and carries a substantial risk of kidney failure. New agency-approved therapies, either specifically for IgAN or for chronic kidney disease (CKD) in general, hold out hope for mitigating renal deterioration in patients with IgAN. The latest addition to this therapeutic armamentarium targets the endothelin-A receptor (ET
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.